Nuvalent, Inc. Class A Common Stock (NUVL) is a publicly traded Healthcare sector company. As of May 21, 2026, NUVL trades at $102.11 with a market cap of $7.89B and a P/E ratio of -17.40. NUVL moved +1.30% today. Year to date, NUVL is +4.47%; over the trailing twelve months it is +34.84%. Its 52-week range spans $55.54 to $113.02. Analyst consensus is strong buy with an average price target of $140.85. Rallies surfaces NUVL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
NUVL financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. NUVL recently traded at $102.11. Market cap is $7.89B. P/E ratio is -17.40. Revenue is $0.
| Metric | Value |
|---|---|
| Price | $102.11 |
| Market Cap | $7.89B |
| P/E Ratio | -17.40 |
| EPS | $-5.85 |
| Dividend Yield | 0.00% |
| 52-Week High | $113.02 |
| 52-Week Low | $55.54 |
| Volume | 536 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-425.38M |
| Gross Margin | 0.00% |
| Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0 | $-425.38M | $-5.85 |
| 2024 | $0 | $-260.76M | $-3.93 |
| 2023 | $0 | $-126.22M | $-2.17 |
| 2022 | $0 | $-81.85M | $-1.65 |
14 analysts cover NUVL: 0 strong buy, 14 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $140.85.